Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3

NCT00324298 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT00324298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00324298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Toxicity Study of Day 2, 3, 8, 15 Short (30 Minute) Versus Day 1, 2, 3 Long (72 Hours) Infusion Bleomycin for Patients With IGCCCG Good Prognosis Germ Cell Tumors, TE3
Lead sponsor
Queen Mary University of London
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2003
Completion date
March 31, 2011
Enrollment
210 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

drug/agent toxicity by tissue/organ, testicular germ cell tumor